Dulaglutide's patent expiry in Japan is a complex issue influenced by multiple patents, some of which have already expired while others remain active [1].
When Does Dulaglutide's Key Patent Expire in Japan?
The primary patent protecting dulaglutide, European Patent EP2627111B1, which is also valid in Japan as JP5642317B, expired on September 24, 2022 [1]. However, this patent covered the composition of matter for dulaglutide [1].
Are There Other Patents Affecting Dulaglutide in Japan?
Yes, there are additional patents related to dulaglutide that extend its protection in Japan. These include patents covering methods of use and formulations. For instance, a patent related to a method of treating diabetes with dulaglutide was set to expire on October 15, 2030 [1]. Another patent concerning the formulation of dulaglutide had an expiry date of January 21, 2032 [1].
Who is Challenging Dulaglutide Patents in Japan?
Information regarding specific companies challenging dulaglutide patents in Japan is not readily available in the provided context. However, patent challenges are common in the pharmaceutical industry as competitors seek to introduce generic versions of drugs.
What is Dulaglutide?
Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes [2]. It is marketed by Eli Lilly and Company under the brand name Trulicity [3].
How Does Patent Expiry Affect Drug Availability and Pricing?
When patents expire, it opens the door for the development and marketing of generic versions of the drug. Generic drugs are typically bioequivalent to their brand-name counterparts but are sold at a lower price, increasing accessibility and competition [4].
When Can Generic Versions of Dulaglutide Be Launched in Japan?
The launch of generic dulaglutide in Japan will depend on the expiry of all relevant patents, including those for formulations and methods of use, as well as any regulatory approvals required for generic products [1]. The expiry of the composition of matter patent on September 24, 2022, did not immediately clear the way for generics if other patents remained in force.
Sources:
[1] DrugPatentWatch.com
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
[3] https://www.drugs.com/trulicity.html
[4] https://www.fda.gov/drugs/generic-drugs/what-generic-drug